Voyager Therapeutics, Inc.
VYGR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $274,610 | $182,453 | $197,222 | $328,716 |
| - Cash | $45,125 | $43,940 | $74,755 | $71,367 |
| + Debt | $38,368 | $40,204 | $41,996 | $43,726 |
| Enterprise Value | $267,853 | $178,717 | $164,463 | $301,075 |
| Revenue | $13,365 | $5,200 | $6,473 | $6,278 |
| % Growth | 157% | -19.7% | 3.1% | – |
| Gross Profit | $13,365 | $5,200 | $6,473 | $6,278 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$26,877 | -$35,560 | -$33,679 | -$37,288 |
| % Margin | -201.1% | -683.8% | -520.3% | -593.9% |
| Net Income | -$27,892 | -$33,382 | -$31,021 | -$34,487 |
| % Margin | -208.7% | -642% | -479.2% | -549.3% |
| EPS Diluted | -0.47 | -0.57 | -0.53 | -0.59 |
| % Growth | 17.5% | -7.5% | 10.2% | – |
| Operating Cash Flow | -$31,048 | -$33,261 | -$37,895 | -$14,529 |
| Capital Expenditures | -$207 | -$1,105 | -$658 | -$155 |
| Free Cash Flow | -$31,255 | -$34,366 | -$38,553 | -$14,684 |